Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple MyelomaAurore Perrot, Jill Corre, Valérie Lauwers‐Cancès et al.|Journal of Clinical Oncology|2019Cited by 179
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Cyrille Hulin et al.|Nature Medicine|2024Cited by 109
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic riskJill Corre, Hervé Avet‐Loiseau, Karim Belhadj et al.|Haematologica|2019Cited by 90